Our proven executive team brings deep, diverse cell therapy and oncology experience and is committed to developing safe, effective, and accessible NK cell therapies for cancer. Artiva's Board of Directors and Advisors bring years of expertise to help us realize the full potential of NK cell therapies.

Fred Aslan, M.D.

President and Chief Executive Officer

Jason Litten, M.D.

Chief Medical Officer

Anne Frese

Vice President, Human Resources

Heather Raymon, Ph.D.

Vice President, Early Development and Program Management

Tom Farrell

Founder and Chief Strategy Officer

Esther van den Boom, CPA

Chief Financial Officer

Eugene Helsel

Vice President, Regulatory Affairs & Quality

Sungyong Won, Ph.D.

Vice President, Alliance Management

Peter Flynn, Ph.D.

Chief Operating Officer

Jennifer Bush

Executive Vice President, General Counsel, Corporate Secretary & Compliance Officer

John Lim, Pharm.D.

Vice President, Clinical Operations

  • Twitter
  • LinkedIn

Privacy Policy  |  Terms
© Artiva Biotherapeutics, Inc., 2020